Ignite Creation Date:
2024-05-05 @ 5:10 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00408395
Status:
COMPLETED
Last Update Posted:
2016-12-01
First Post:
2006-12-05
Brief Title:
Safety and Immunogenicity of 2 Commercially Available Influenza Vaccines in Children
Sponsor:
Novartis Vaccines
Organization:
Novartis
Study Overview
Official Title:
A Phase II Observer-Blind Randomized Parallel Groups Multicenter Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of One and Two 025 mL Intramuscular Doses of a Commercially Available Influenza Vaccine Versus Two 025 mL Intramuscular Doses of a Commercially Available Influenza Vaccine in Healthy Children
Status:
COMPLETED
Status Verified Date:
2011-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study of the safety and immunogenicity of three commercially available influenza vaccines in children
Detailed Description:
A Phase II Observer-Blind Randomized Parallel Groups Multicenter Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of One and Two 025 mL Intramuscular Doses of a commercially available influenza vaccine versus Two 025 mL Intramuscular Doses of a commercially available influenza vaccine in Healthy Children
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006-003181-34 | None | None | None |